Corona Remedies Ltd share price inched up 0.38% to Rs 2097.6 after the company's net profit soared by 32.61% to Rs 60.11 crore, while revenue from operations gained 19.64% to Rs 422.43 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 5.89%. It has marginally improved by 2.79% over last one week and jumped by 15.59% in last one month while the market capitalization of Corona Remedies Ltd has softened by 0.78% and 21.60% in the same period respectively. Profit before tax (PBT) of Corona Remedies Ltd stood at Rs 80.36 crore in Q2 FY26, jumping 32.41% year-on-year, and expanding by 46.80% quarter-on-quarter. EBITDA came in at Rs 90 crore, surging by 32.79% YoY and rallying 55.38% sequentially. Total expenses advancing by 13.66% to Rs 342.54 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 32.65 crore, increasing 17.74% YoY, while employee benefits expense was at Rs 122.09 crore, witnessing a strong rise of 14.50% YoY. For the TTM ended FY26, revenue from operations grew 17.28% to Rs 1403.18 crore, while net profit jumped 23.88% to Rs 185.12 crore, compared to previous TTM. EBITDA jumped by 23376% to Rs 282.79 crore, and PBT soared 21.10% to Rs 240.42 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 229.48 crore in FY26, as against Rs 190.5 crore in FY25. Corona Remedies Ltd surged by 45.95% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.81% during the same period.
